Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Nicolas Gonzalez Castro

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Cell|April 23, 2024
Integrative spatial analysis reveals a multi-layered organization of glioblastomaAlissa C Greenwald, Noam Galili Darnell, Rouven Hoefflin, et al.
Nature|February 26, 2025
Programs, origins and immunomodulatory functions of myeloid cells in gliomaTyler E Miller, Chadi A El Farran, Charles P Couturier, et al.
Neuro-Oncology Advances|February 16, 2026
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitorsVihang Nakhate, Catharina Westergaard, Zhou Lan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Nature|May 31, 2023
Hallmarks of transcriptional intratumour heterogeneity across a thousand tumoursAvishai Gavish, Michael Tyler, Alissa C Greenwald, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Cancer Cell|April 5, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaAvishay Spitzer, Simon Gritsch, Masashi Nomura, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Cell|April 23, 2024
Integrative spatial analysis reveals a multi-layered organization of glioblastomaAlissa C Greenwald, Noam Galili Darnell, Rouven Hoefflin, et al.
Nature|February 26, 2025
Programs, origins and immunomodulatory functions of myeloid cells in gliomaTyler E Miller, Chadi A El Farran, Charles P Couturier, et al.
Neuro-Oncology Advances|February 16, 2026
Evaluation of sex differences in survival among glioblastoma patients treated with immune checkpoint inhibitorsVihang Nakhate, Catharina Westergaard, Zhou Lan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2023
Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent GlioblastomaGilbert Youssef, Rifaquat Rahman, Camden Bay, et al.
Nature|May 31, 2023
Hallmarks of transcriptional intratumour heterogeneity across a thousand tumoursAvishai Gavish, Michael Tyler, Alissa C Greenwald, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Cancer Cell|April 5, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaAvishay Spitzer, Simon Gritsch, Masashi Nomura, et al.
Neuro-Oncology|May 29, 2025
Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4Aleksandra B Lasica, Zhou Lan, Julie J Miller, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Neuro-Oncology|October 14, 2022
Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directionsJulie J Miller, L Nicolas Gonzalez Castro, Samuel McBrayer, et al.
Pageof 5